company background image
2VN logo

Biohaven Pharmaceutical Holding DB:2VN Stock Report

Last Price

€153.00

Market Cap

€11.0b

7D

-1.9%

1Y

24.8%

Updated

03 Oct, 2022

Data

Company Financials +

Biohaven Pharmaceutical Holding Company Ltd.

DB:2VN Stock Report

Market Cap: €11.0b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

2VN Stock Overview

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases.

2VN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Biohaven Pharmaceutical Holding Company Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biohaven Pharmaceutical Holding
Historical stock prices
Current Share PriceUS$153.00
52 Week HighUS$158.00
52 Week LowUS$78.50
Beta1.04
1 Month Change2.69%
3 Month Change10.07%
1 Year Change24.80%
3 Year Change292.31%
5 Year Change461.49%
Change since IPO654.07%

Recent News & Updates

Recent updates

Shareholder Returns

2VNDE BiotechsDE Market
7D-1.9%3.3%1.6%
1Y24.8%35.8%6.4%

Return vs Industry: 2VN exceeded the German Biotechs industry which returned -10.9% over the past year.

Return vs Market: 2VN exceeded the German Market which returned -26.6% over the past year.

Price Volatility

Is 2VN's price volatile compared to industry and market?
2VN volatility
2VN Average Weekly Movement1.8%
Biotechs Industry Average Movement5.9%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 2VN has not had significant price volatility in the past 3 months.

Volatility Over Time: 2VN's weekly volatility has decreased from 11% to 2% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013928Vlad Corichttps://www.biohavenpharma.com

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases. Its portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have four migraine attacks per month. It is also developing a pipeline of late-stage product candidates across five mechanistic platforms, including CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia; MPO inhibition for amyotrophic lateral sclerosis; and Kv7 Ion Channel Activators (Kv7) for focal epilepsy and neuronal hyperexcitability, as well as myostatin inhibition for neuromuscular diseases.

Biohaven Pharmaceutical Holding Company Ltd. Fundamentals Summary

How do Biohaven Pharmaceutical Holding's earnings and revenue compare to its market cap?
2VN fundamental statistics
Market cap€10.99b
Earnings (TTM)-€1.04b
Revenue (TTM)€873.87m

12.6x

P/S Ratio

-10.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2VN income statement (TTM)
RevenueUS$859.68m
Cost of RevenueUS$276.59m
Gross ProfitUS$583.10m
Other ExpensesUS$1.60b
Earnings-US$1.02b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-14.29
Gross Margin67.83%
Net Profit Margin-118.82%
Debt/Equity Ratio-125.1%

How did 2VN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.